Showing 1711-1720 of 3038 results for "".
- Outlook Therapeutics Receives FDA Agreement Under SPA for 90 Day Noninferiority Study, NORSE EIGHThttps://modernod.com/news/outlook-therapeutics-receives-fda-agreement-under-special-protocol-assessment-for-90-day-noninferiority-study-norse-eight/2482077/Outlook Therapeutics announced that it has received written agreement from the FDA under a special protocol assessment (SPA) for the NORSE EIGHT clinical trial protocol evaluating ONS-5010 in wet age-related macular degeneration (AMD) subjects. Additionally, Outlook Therapeutics announc
- Prevent Blindness Opens Nominations for the 2024 Jenny Pomeroy Award for Excellence in Vision and Public Health, and Rising Visionary Awardhttps://modernod.com/news/prevent-blindness-opens-nominations-for-the-2024-jenny-pomeroy-award-for-excellence-in-vision-and-public-health-and-rising-visionary-award/2482043/Prevent Blindness is issuing the call for nominations for the “2024 Jenny Pomeroy Award for Excellence in Vision and Public Health,” and the fifth annual “
- Nordic Pharma Completes Acquisition of Visant Medical; Plans to Launch Lacrifill in the US for Dry Eye Diseasehttps://modernod.com/news/nordic-pharma-completes-acquisition-of-visant-medical-plans-to-launch-lacrifill-in-the-us-for-dry-eye-disease/2482021/Amring Pharmaceuticals, a subsidiary of Nordic Group BV (Nordic Pharma), announced the completion of its acquisition of Visant Medical. Financial terms of the deal were not disclosed. The companies say the acquisition unites Nordic Pharma's pharmaceutical e
- NORA Names New Executive and Advisory Board Membershttps://modernod.com/news/nora-names-new-executive-and-advisory-board-members/2481983/The Neuro-Optometric Rehabilitation Association, International (NORA) announced the appointments of its new Executive and Advisory Board members. NORA is an interdisciplinary group of professionals dedicated to providing a complete ocular health evaluation and optimum visual rehabilitation educat
- Amydis Launches Phase 2 Glaucoma Clinical Program Using Novel Retinal Tracer to Detect Amyloid Betahttps://modernod.com/news/amydis-launches-phase-2-glaucoma-clinical-program-using-novel-retinal-tracer-to-detect-amyloid-beta/2481939/Amydis announced it has launched a phase 2 clinical program for its novel retinal tracer, AMDX-2011P, to detect amyloid-beta in glaucoma patients. "Multiple diagnostic tests detect structural and vascular changes in the retina associated with glaucoma while visual function tes
- Zeiss Expands its Clinical Workflows and Digital Portfolio at AAO 2023https://modernod.com/news/zeiss-expand-its-clinical-workflows-and-digital-portfolio-at-aao-2023/2481915/Zeiss Medical Technology will showcase digital enhancements to the cataract, corneal refractive, and retina workflows at the American Academy of Ophthalmology (AAO) conference from Nov. 4-6, 2023, in San Francisco. As part of the Zeiss Medical Ecosystem, these innovations offer new digital tools
- Erin Powers Joins J&J Vision as Vice President of US Sales and Marketing for its Surgical Vision Portfoliohttps://modernod.com/news/erin-powers-joins-jj-vision-as-vice-president-of-us-sales-and-marketing-for-its-surgical-vision-portfolio/2481838/Johnson & Johnson announced the appointment of Erin Powers to the position of Vice President of US Sales and Marketing for its Surgical Vision portfolio. Ms. Powers will lead the US sales, marketing, and professional education teams, and will join the company within t
- NovaBay Pharmaceuticals’ Avenova Allograft is Launched in the United Stateshttps://modernod.com/news/novabay-pharmaceuticals-avenova-allograft-is-launched-in-the-united-states/2481830/NovaBay Pharmaceuticals announced the launch of the Avenova Allograft in the United States through its physician-dispensed channel. The company’s prescription optic allograft, which is intended for use as a protective covering during the repair of ocular surfaces, is manufactured using BioS
- NeoLight’s Icon Go With Fluorescein Angiography Capabilities Cleared by FDA for Portable Retinal Imaginghttps://modernod.com/news/neolights-icon-go-with-fluorescein-angiography-capabilities-cleared-by-fda-for-portable-retinal-imaging/2481829/NeoLight announced FDA Class II clearance for its Icon Go portable ophthalmic retinal imaging system with expanded fluorescein angiography (FA) capabilities. The Icon Go retinal diagnostics device is designed to provide retinal imaging across diverse patient care environments
- Novartis to Discontinue Development of GA Gene Therapyhttps://modernod.com/news/novartis-to-discontinue-development-of-ga-gene-therapy/2481824/Following weak phase 2 clinical data, Novartis decided to discontinue the clinical development of its geographic atrophy gene therapy candidate GT005, which it acquired as part of its acquisition of Gyroscope Therapeutics. The announcement was made by investment film Syncona, which prev